BioRestorative Therapies (BRTX) stock price, revenue, and financials

BioRestorative Therapies market cap is $8.8 k, and annual revenue was $111 k in FY 2018

$8.8 K

BRTX Mkt cap, 22-Apr-2020

$38 K

BioRestorative Therapies Revenue Q3, 2019
BioRestorative Therapies Net income (Q3, 2019)-5.1 M
BioRestorative Therapies EBIT (Q3, 2019)-1.8 M
BioRestorative Therapies Cash, 30-Sept-201998.1 K
BioRestorative Therapies EV7.6 M

BioRestorative Therapies Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

15.6k1.7k416.0k628.9k36.4k81.0k111.0k

Revenue growth, %

24662%51%(94%)

Cost of goods sold

1.3k208.0213.8k261.5k102.0

Gross profit

14.3k1.5k202.2k367.4k36.3k

Gross profit Margin, %

92%88%49%58%100%

Sales and marketing expense

103.7k132.0k115.0k125.6k168.4k86.5k65.5k352.2k

R&D expense

12.0k416.2k1.6m1.4m2.1m2.9m2.2m1.5m

General and administrative expense

1.4m1.2m2.3m2.3m3.9m3.3m3.9m4.0m

Operating expense total

1.5m5.6m4.8m5.1m7.5m7.8m8.5m5.9m

EBIT

(3.6m)(5.6m)(4.8m)(4.9m)(7.2m)(7.8m)(8.4m)(7.6m)

EBIT margin, %

(35746%)(282873%)(1183%)(1140%)(21448%)(10339%)(6890%)

Interest expense

260.0k591.8k998.9k665.1k753.1k839.0k1.1m4.9m

Interest income

Pre tax profit

(5.6m)(7.9m)(8.6m)(9.4m)

Income tax expense

Net Income

(4.1m)(6.5m)(5.8m)(5.6m)(7.9m)(8.6m)(9.4m)(12.5m)

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

10.0k5.2k1.1k125.0375.0175.9k159.9k184.9k148.8k96.1k9.1k16.2k5.0k7.0k20.0k16.0k19.0k37.0k26.0k29.0k31.0k38.0k

Cost of goods sold

1.3k162.010.060.042.4k66.1k76.4k74.6k50.9k10.071.0

Gross profit

4.0k968.0115.0315.0133.6k93.8k108.5k74.1k45.2k9.1k16.1k

Gross profit Margin, %

76%86%92%84%76%59%59%50%47%100%100%

Sales and marketing expense

17.0k36.9k40.0k30.6k15.0k29.9k17.4k31.8k15.5k41.8k44.9k49.1k22.5k18.2k15.6k29.1k9.1k7.0k41.0k17.5k155.2k15.8k108.8k156.2k

R&D expense

2.1k54.7k189.6k400.4k414.9k493.7k293.3k290.7k406.9k452.5k615.6k866.0k608.7k656.2k805.9k610.7k490.7k407.1k372.8k357.4k455.0k441.7k409.8k

General and administrative expense

443.5k475.1k358.8k371.7k255.0k640.1k513.9k636.0k548.6k502.8k917.6k696.4k596.5k902.9k982.4k610.7k1.2m1.1m738.1k1.4m1.3m284.5k1.3m1.1m917.0k

Operating expense total

460.5k512.0k400.8k457.0k1.2m1.3m1.1m1.4m1.4m989.8k1.7m1.3m1.5m2.1m2.2m1.7m2.5m2.6m1.8m1.8m1.7m797.1k1.8m1.6m1.5m

EBIT

(1.0m)(853.0k)(1.3m)(1.4m)(1.2m)(1.3m)(1.1m)(1.4m)(1.3m)(896.0k)(1.6m)(1.3m)(1.5m)(2.1m)(2.1m)(1.7m)(2.5m)(2.6m)(1.7m)(2.2m)(2.1m)(1.2m)(2.3m)(2.1m)(1.8m)

EBIT margin, %

(13928%)(23066%)(115007%)(903202%)(380911%)(728%)(560%)(879%)(849%)(1550%)(22654%)(13266%)(34304%)(35562%)(12845%)(10898%)(11741%)(5541%)(4572%)(8029%)(6867%)(4787%)

Interest expense

166.6k160.4k127.1k164.1k172.4k197.9k174.0k241.3k51.7k204.4k134.2k157.5k80.6k420.2k115.3k118.7k296.4k178.2k308.5k276.9k1.5m1.7m1.6m2.0m3.2m

Interest income

Net Income

(1.2m)(1.0m)(1.5m)(1.6m)(1.5m)(1.6m)(1.3m)(1.7m)(1.3m)(1.1m)(1.8m)(1.4m)(1.6m)(2.5m)(2.3m)(1.8m)(2.8m)(2.7m)(2.1m)(2.5m)(3.5m)(2.9m)(3.9m)(4.2m)(5.1m)

BioRestorative Therapies Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

71.5k363.0201.1k91.8k166.6k31.8k451.7k117.5k

Accounts Receivable

93.4k6.0k38.0k29.0k

Prepaid Expenses

46.9k18.4k20.7k20.6k29.3k30.0k34.5k

Inventories

12.5k18.0k1.9k

Current Assets

118.4k31.3k239.8k114.3k289.3k61.7k519.7k181.0k

PP&E

94.8k59.4k35.6k493.9k643.1k508.6k327.8k175.2k

Total Assets

221.0k1.3m1.4m1.7m2.0m1.6m1.8m1.2m

Accounts Payable

426.2k771.4k1.3m1.1m2.5m2.3m2.5m1.9m

Short-term debt

3.0m961.7k5.0m5.7m1.0m3.5m3.6m

Current Liabilities

3.9m2.8m7.5m8.5m5.6m5.8m8.4m9.3m

Long-term debt

3.6m524.0k50.0k302.0k194.3k523.9k

Total Debt

3.0m4.6m5.7m3.7m4.1m

Total Liabilities

3.9m6.4m8.1m8.6m5.9m6.6m8.6m9.8m

Common Stock

635.6k772.2k19.6k34.5k3.3k6.1k11.7k

Preferred Stock

Additional Paid-in Capital

3.2m8.2m13.1m18.5m29.4m37.0m44.6m55.3m

Retained Earnings

(25.4m)(33.3m)(42.0m)(51.4m)(63.9m)

Total Equity

(3.7m)(5.1m)(6.7m)(6.9m)(3.9m)(5.0m)(6.8m)(8.6m)

Financial Leverage

-0.1 x-0.2 x-0.2 x-0.2 x-0.5 x-0.3 x-0.3 x-0.1 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

7.2k14.6k3.1k12.6k104.1k498.6k119.0642.0110.4k59.2k374.0k145.9k6.4k12.8k353.1k516.2k6.3k8.9k1.9k734.08.6k3.5k105.4k496.3k1.3m98.1k

Accounts Receivable

51.0k9.0k16.0k5.0k7.0k20.0k16.0k19.0k37.0k26.0k29.0k31.0k38.0k

Prepaid Expenses

58.2k49.6k8.5k34.6k25.2k53.4k52.3k47.7k9.1k18.1k30.2k32.4k34.1k28.5k22.1k14.0k21.3k22.4k24.7k19.6k17.3k35.1k50.7k122.0k42.4k64.7k

Inventories

13.8k13.8k18.0k17.9k17.8k17.4k1.9k2.5k2.5k

Current Assets

65.4k64.2k11.6k47.1k129.3k565.8k66.2k66.3k137.3k95.0k421.5k180.2k246.1k385.0k384.2k546.2k32.6k38.2k46.6k36.3k44.9k75.6k182.0k647.3k1.4m200.9k

PP&E

412.3k330.8k68.9k78.5k69.0k50.1k41.2k32.7k25.5k18.3k73.6k537.2k702.3k662.5k599.4k602.4k555.6k463.0k416.6k369.6k286.0k256.5k213.8k141.3k136.4k105.6k

Total Assets

485.6k402.8k88.1k1.3m1.4m1.8m1.2m1.2m1.3m1.2m1.6m1.9m2.1m2.2m2.0m2.2m1.6m1.5m1.4m1.4m1.2m1.2m1.3m1.6m2.4m1.5m

Accounts Payable

308.5k658.3k739.2k440.0k699.8k773.3k1.0m1.2m1.2m893.4k774.1k1.3m1.7m2.1m2.2m2.1m2.0m2.3m2.5m2.7m2.4m2.3m2.1m1.6m1.5m1.7m

Short-term debt

1.9m2.3m3.1m4.3m4.6m938.0k979.1k5.0m5.2m5.9m5.2m5.5m1.1m1.2m1.3m1.3m1.3m1.9m2.4m2.9m3.7m4.5m3.2m3.5m5.5m7.5m

Current Liabilities

2.8m3.7m4.4m5.6m6.5m3.1m3.4m7.9m7.9m8.3m7.4m8.9m4.9m5.5m5.6m5.7m5.5m6.1m7.0m8.0m8.8m10.7m8.9m8.7m11.1m13.7m

Long-term debt

153.7k3.6m3.6m275.0k76.7k622.7k307.9k30.0k422.2k499.3k487.0k137.6k120.1k61.7k84.4k368.7k1.2m488.1k200.8k157.1k

Total Debt

2.1m2.3m3.1m4.3m4.6m4.5m4.6m5.0m5.5m6.0m5.8m5.8m1.1m1.7m1.3m1.8m1.8m2.1m2.6m2.9m3.8m4.8m4.3m4.0m5.7m7.7m

Total Liabilities

3.0m3.7m6.6m7.0m7.9m8.2m8.3m8.1m9.3m5.0m5.9m5.6m6.2m6.1m6.2m7.1m8.1m8.9m11.1m10.2m9.2m11.4m13.9m

Common Stock

584.6k603.2k655.9k701.0k717.8k17.0k17.3k17.7k22.4k25.6k31.6k37.8k2.8k2.9k4.0k4.2k4.4k5.3k5.5k5.6k6.5k6.7k8.7k14.7k19.8k23.7k

Preferred Stock

Additional Paid-in Capital

2.7m2.9m4.1m5.7m6.4m10.8m11.2m11.6m14.5m15.7m17.5m19.8m25.7m26.5m32.3m34.1m35.4m40.0m41.8m42.8m46.2m47.6m51.4m60.1m63.0m64.6m

Retained Earnings

(27.2m)(28.6m)(30.2m)(35.8m)(38.1m)(39.9m)(44.7m)(47.5m)(49.5m)(53.9m)(57.4m)(60.4m)(67.8m)(72.0m)(77.0m)

Total Equity

(2.5m)(3.3m)(4.3m)(4.3m)(5.1m)(4.8m)(5.7m)(6.6m)(7.0m)(7.1m)(6.5m)(7.4m)(2.9m)(3.8m)(3.5m)(4.0m)(4.5m)(4.7m)(5.7m)(6.7m)(7.7m)(9.9m)(8.9m)(7.7m)(8.9m)(12.4m)

Debt to Equity Ratio

-0.7 x

Debt to Assets Ratio

34.7 x

Financial Leverage

-0.2 x-0.1 x0 x-0.3 x-0.3 x-0.4 x-0.2 x-0.2 x-0.2 x-0.2 x-0.2 x-0.3 x-0.7 x-0.6 x-0.6 x-0.5 x-0.4 x-0.3 x-0.2 x-0.2 x-0.2 x-0.1 x-0.1 x-0.2 x-0.3 x-0.1 x

BioRestorative Therapies Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(2.3m)(3.3m)(1.5m)(3.1m)(4.6m)(1.6m)(2.8m)(4.1m)(1.7m)(3.0m)(4.1m)(1.8m)(3.2m)(4.8m)(2.5m)(4.7m)(6.6m)(2.8m)(5.5m)(7.6m)(2.5m)(6.0m)(8.9m)(3.9m)(8.0m)(13.1m)

Depreciation and Amortization

52.4k77.7k26.0k36.4k63.4k26.7k53.1k79.1k25.5k50.1k73.9k39.6k89.5k150.6k62.4k127.2k192.7k64.3k129.5k195.2k60.6k121.6k183.1k52.7k105.6k161.4k

Accounts Receivable

(51.0k)84.4k77.4k88.4k(1.0k)(14.0k)(10.0k)19.0k1.0k12.0k(2.0k)(9.0k)

Inventories

(1.3k)(1.3k)(5.5k)61.0175.0580.018.0(547.0)(547.0)

Accounts Payable

148.3k498.1k313.0k13.8k273.7k1.8k231.6k384.8k(59.4k)(369.0k)(488.4k)80.5k313.4k629.9k(265.1k)(377.2k)(421.9k)15.0k215.6k410.0k(68.9k)(177.7k)(342.7k)(289.8k)(457.4k)(379.0k)

Cash From Operating Activities

(1.4m)(1.7m)(393.9k)(1.7m)(2.1m)(771.8k)(1.5m)(1.9m)(806.7k)(1.8m)(2.6m)(674.8k)(1.5m)(2.1m)(1.7m)(2.7m)(3.9m)(1.2m)(2.0m)(2.5m)(1.2m)(2.2m)(3.6m)(2.0m)(3.4m)(5.1m)

Purchases of PP&E

(17.8k)(17.8k)(2.5k)(2.5k)(1.5k)(92.2k)(151.9k)(360.5k)(89.9k)(151.2k)(181.9k)(12.9k)(12.9k)(29.4k)(35.6k)

Cash From Investing Activities

(17.8k)14.2k(1.0m)(1.0m)980.0980.0(546.0)(167.2k)(226.9k)(435.5k)(89.9k)(151.2k)(181.9k)(12.9k)(12.9k)(29.4k)(35.6k)

Short-term Borrowings

(209.9k)(209.9k)(50.0k)(50.0k)(50.0k)(4.0k)(25.0k)(53.0k)(53.0k)(103.5k)(118.5k)(476.5k)(74.0k)(74.0k)(114.0k)(119.6k)(149.4k)(433.3k)(1.3m)(2.2m)(3.5m)

Cash From Financing Activities

1.4m1.7m325.5k2.6m3.1m1.3m1.5m1.9m715.0k1.6m2.8m896.0k1.6m2.4m2.0m3.2m4.0m1.2m2.0m2.5m715.1k1.8m3.2m2.4m4.6m5.1m

Net Change in Cash

(10.9k)(3.5k)(68.4k)(58.9k)32.6k498.2k(244.0)279.0(90.7k)(141.9k)172.9k54.1k(85.4k)(79.0k)186.5k349.6k(160.2k)(23.0k)(29.9k)(31.1k)(443.1k)(448.2k)(346.3k)378.8k1.2m(19.4k)

Interest Paid

36.3k95.1k114.8k266.4k379.1k16.1k29.1k36.9k16.8k43.8k76.1k36.5k46.2k59.6k10.0k15.0k30.4k11.0k11.0k11.0k9.2k9.4k21.6k126.2k134.5k232.7k

BioRestorative Therapies Ratios

USDQ2, 2011

Financial Leverage

-0.2 x